In the clinical practice of hematopoietic SCT, the minimum numbers of cells required for a successful engraftment are defined on the basis of their CD45 and CD34 expression profiles. However, the quantity of earlier progenitors or CD34-positive cells at different differentiation stages within stem cell grafts is not generally taken into consideration. During the last decade, various teams have quantified the number of cells expressing various combinations of CD34, CD38, CD133, CD90 co-expression and/or aldehyde dehydrogenase functional capacity using flow cytometry. Some of these studies resulted in the greater appreciation that combinations of these Ags were associated with varied myeloid, erythroid and platelet engraftment rates whereas others showed that the relative absence or presence of these markers could define cells responsible for either short-or long-term engraftment. These findings were also extended to differences between progenitor cell populations found within BM vs peripheral or cord-blood grafts. Cells harvested from donors are also generally frozen and stored; thawed cells have variable levels of viability and functional capacity based on the time tested post thaw, which also can be assessed by flow cytometry. Finally, flow cytometry has the potential for analysis of cells carrying a mesenchymal stem cell phenotype, which may be quiescent within some of the stem cell products. This review will address the need for stem cell subpopulation quantification and summarize existing published data to identify some Ags and functional characteristics that can be applicable to daily clinical practice.
INTRODUCTION
It is now almost 50 years since allogeneic BMT (alloBMT) was introduced to the field of clinical hematology. 1 Over this time period alloBMT has earned the title of a 'standard treatment' modality for an expanding number of hematological diseases. Developing cytotherapeutic techniques and utilization of recombinant hematopoietic growth factors has made both allogeneicand autologous-mobilized PBSC transplantation possible. The mobilization and engraftment kinetics have been investigated extensively in experimental and clinical models. These studies have led to certain guidelines regarding the optimal number of hematopoietic stem cells (HSC) to be collected and infused following their thawing. These counts are based on the numbers of cells expressing CD34 (a surface sialomucin) on CD45dim þ mononuclear cells. 2 Although initially beset by varied preparative techniques, several workshops and international collaborations have resulted in a consensus on methodology and commercialized standard platforms for worldwide application. Organizations such as the European Group for Blood & Marrow Transplantation (EBMT) and International Society of Hematotherapy and Graft Engineering (ISHAGE) recommend that laboratories have external quality controls so as to be able to compare results across national borders. 3 Use of a minimum of 2 Â 10 6 cells/kg for autologous and higher numbers of cells for allogeneic/unrelated PBSC transplantation are recommended in the EBMT handbook. However, these recommendations have opened up new discussions and areas in need of further clarification. In addition to CD34 þ cells, sources of HSC such as BM, growth factor-mobilized PB and cord blood (CB) additionally contain CD34À cells as well as early progenitors of myelopoiesis. 4 This review will focus not only on the different subpopulations of HSCs that are quantified by current routine flow cytometric methods and their impact on transplantation kinetics, but also on the differences between traditional HSCs and earlier progenitor cells that are committed to generate cells of myeloid lineage. Do CD34 counts always predict neutrophil and platelet engraftment successfully? The existing recommendations about the minimum number of HSCs to be used for transplantation have been acquired predominantly from retrospective data. 3, 5, 6 There are reports demonstrating faster neutrophil or platelet engraftment with increasing doses of HSCs in the autologous setting. 5, 7, 8 The numbers of HSC to be transplanted during BMT is calculated by dividing the total number of cells infused to the actual body weight. As patients may develop weight loss resulting from bone resorbtion, and/or fat or muscle loss, investigators aimed to analyze the impact of actual body weight or ideal body weight on engraftment. These investigators were able to show correlation between engraftment speed and HSC/ideal body weight, but not with HSC/actual body weight. Thus, Singh et al. 9 have recommended use of ideal body weight for this purpose.
Furthermore, Allan et al. 10 have drawn attention not solely to the count of harvested cells, but also the numbers of CD34 þ cells recovered post thaw and subsequently infused, as critical. When cell numbers o2 Â 10 6 , 2--5Â 10 6 or 45 Â 10 6 per kg were compared, decreased HSC counts were found to influence platelet but not neutrophil-recovery speed. A decrease in CD34 þ cell counts from 5 to 3 Â 10 6 per kg after thawing did not prevent rapid engraftment. However, values that were between 2.9 and 1.7 led to a delay in engraftment. The actual mononuclear cell subpopulations lost during cryopreservation and thawing procedures are unknown, and have not been sufficiently studied.
There is accumulating evidence suggesting that more complex mechanisms are involved in the mobilization of stem cells, in that specific mobilization protocols impact the HSC content of the resulting grafts. For example, use of chemotherapeutic agents in addition to myeloid growth factors augment the myelosupression, resulting in an amplified rebound and surge of HSC into the circulation. However, these cells do not result in a more rapid recovery for the patient. It remains perplexing that we are able to mobilize increased numbers of HSC with fewer apheresis procedures, but still not achieve more rapid engraftment. The cellular and molecular mechanisms underlying these observations remain unclear. It was suggested that the cytotoxic damage by chemotherapy on MSC may lead to mobilization of numerically more HSCs, but that these have inherently poorer functional capacity and do not increase the kinetics of engraftment. Lazarus et al. 11 were the first to obtain MSCs from patient BM grafts whereas they were not able to repeat these with PBSC from normal donors or patients. It is postulated that the CD34 þ cells mobilized following G-CSF, or G-CSF and chemotherapy have different adhesion phenotypes and repopulating potentials as well. 12, 13 Our current knowledge of basic stem-cell biology in the research setting has provided most of the insights into the mechanisms of stem-cell activity and has thus influenced the protocols used in clinical practice. Such investigations have helped define that HSCs are generally quiescent cells that are capable of asymmetric replication with the capacity to either self-renew or develop into more differentiated progenitors, responding to need. Self-renewal is the process by which a stem cell divides and produces a daughter cell with identical potential and capacity. The second hallmark characteristic of a stem cell is its capacity to repopulate a given system via a variety of downstream multipotent progenitors. 14 In addition to HSCs, BM appears to be the origin of additional stem cells such as MSC that are also capable of differentiating to progenitors of mature cell populations of hematopoiesis, as well as many other tissues such as cartilage, muscle and bone. 15 --18 There is a need for analysis and quantification of HSC subpopulations and earlier myeloid progenitors with marrow-repopulating capacity. In the absence of information on the number of earlier progenitors transplanted in clinical practice, many questions regarding engraftment failure and delay will remain unsolved.
HSC subpopulations that have been defined and associated with clinical outcome With the increasing number of BM and peripheral stem cell transplants being performed, the need to more carefully define hematopoietic subpopulations began in earnest about 10 years ago, and was facilitated greatly by the use of combinations of MoAbs recognizing surface structures on stem and progenitor cell subpopulations. As the repertoire of available Ab reagents expanded, far more exquisite characterization became possible; some of these reagents are summarized in Table 1 . HSCs are relatively rare within normal BM, being present at levels in the range of 1 in 10 4 --10 5 cells. 21 Although these are relatively low frequency cell types, current cytometric technology permits their detailed immunophenotypic analysis. Flow cytometry is a very powerful investigative tool that enables researchers to characterize subpopulations based on their immunophenotype or functional properties. 20 Table 2 summarizes the impact of flow cytometric stem cell-marker expression on engraftment kinetics. CD133 (AC133) is a transmembrane cell surface marker that belongs to the prominin family of pentaspan membrane proteins, and is expressed on hematopoietic stem and progenitor cells. 33, 34 Jamie-Perez et al. 28 have quantified CD133 þ HSC within PB and grafts following stem-cell mobilization in the autologous setting.
They were able to demonstrate a significant correlation between CD133 þ and CD34 þ HSCs in the PB before collection and in the final product for grafting (r ¼ 0.62 and 0.64; Po0.01). There was a stronger correlation between CD34 þ cells and CD133 þ cells in the leukapheresis product (r ¼ 0.94) compared with pre-collection PB (r ¼ 0.33; Po0.01). However, time to recovery did not correlate with the number of CD133 þ HSCs infused.
With an aim to analyze the human hematopoietic precursors in all stem-cell sources Arber et al.
32 initiated a study on 26 patients. These investigators demonstrated the presence of distinct distributions of defined HSC and progenitor cell subpopulations within the lineage negative (linÀ) CD34 þ compartment. On the basis of published data the most frequently observed subpopulations are summarized in Table 3 . Investigators found all these subpopulations' cell counts to be variable in distribution and numbers, depending on both the source of stem cells (BM, mobilized peripheral or CB) and the chronological age of the donor. Moreover, they were able to show that platelet and reticulocyte engraftment post transplant was correlated with the presence of the common myeloid progenitor and megakaryocyte --erythroid progenitor compartments, and that an improved understanding of these defined compartments could have beneficial effects on future cellular-based therapies.
Functional assessment of HSCs using aldehyde dehydrogenase (ALDH) and dyes Stem cells produce the detoxifying enzyme ALDH, which distinguishes them from more differentiated cells. ALDH-producing cells can be detected by flow cytometry, with those coexpressing CD34 and ALDH activity identifying those cells with maximum repopulating potential. 30,36 --39 Within the ALDH-expressing subpopulation, HSCs are enriched within the ALDH bright þ segment although ALDH bright þ -expressing cells do not necessarily repopulate immunodeficient mice. 36 Cells that coexpress ALDH and CD133 are also potent stem cells with high engraftment capacity with 65% of CD34 þ CD133 þ cells expressing additionally high levels of ALDH. 17 In contrast, cells with low ALDH have been shown to exert a healing effect following an ischemia-induced skin necrosis model suggesting endothelial progenitor cell capacity.
Quantitation of stem cells based on their functional properties is an exciting approach and theoretically more relevant than relying solely on the numbers of immunophenotyped cells harvested, and subsequently thawed and infused. As stem cells posses p-glycoprotein ABC transporters to protect them from environmental toxins and threats, high efflux of dyes such as Hoechst 33342 or Rhodamine 123 have been used successfully to characterize cell function. Following this approach investigators have identified side populations in the circulation of normal human blood based on initial studies that detected the highest hematopoietic repopulation potential in side population cells obtained from murine BM. 40, 41 Unfortunately, the impact of the number of cells belonging to the side population within a graft has not yet been fully investigated in human patients. The human linÀ BM mononuclear cell population, LinÀCD34 þ CD38 low /À cells also generally express ALDH activity, but they are especially enriched within the combined side population/ ALDHbright þ subpopulation. 42, 43 There is growing evidence that the selection of stem cells might be improved based on their ALDH expression. Human BM mononuclear cells, sorted on the basis of their low side light scatter (SSC low ) ALDH bright þ , make up 1.2% of all nucleated cells. Fallon et al. 29 were the first to analyze the relationship between the levels of ALDH-expressing cell counts in the graft and resulting engraftment. Interestingly, they were able to detect a correlation between engraftment and SSC low ALDH bright þ , but not CD34 þ cell numbers in fresh autologous PBSC transplants. Recently, Gunduz et al. 31 quantified the SSC low ALDH bright þ cells in PB and autologous grafts, and were able to define thresholds for engraftment (Table 2) . Lioznov et al. 30 investigated the relationship between engraftment following allogeneic transplantation and the number of cells expressing ALDH activity. Surprisingly, they found that ALDH activity not always correlated with CD34 counts, but rather could better predict both colonyforming potential and post-transplant donor chimerism. Moreover, the CD34 counts were influenced by storage of PB or BM stem cells at 41C or room temperature, and correlated less with colonyforming unit (CFU) compared with ALDH activity. Continuously increasing use of cryopreserved stem cell products, namely CB or unrelated products that are subject to long transportation hours, favors the need to use either ALDH activity or colony forming assays to measure the remaining stem cell functions in the product infused. Certainly, ALDH activity quantification by flow cytometry can be accomplished reliably and faster than CFU tests. Although flow cytometry is the gold standard for measuring ALDH activity, such information is yet to attain a level of utility to suggest its implementation into clinical practice. 44 ALDH isoenzymes are being defined and among many, ALDH1A1 and ALDH31 are the ones most effective on self-protection, differentiation and cellular expansion of stem cells. ALDH activity is not only exclusive to HSCs but also can be expressed by cancer stem cells and progenitors of tissues with regenerative potential. 44 Results from preclinical trials conducted by Aldagen Inc. (Durham, NC, USA) suggest the angiogenic potential of ALDH-bright cell population in human CB. As ALDH has a cell cycle-control role on HSCs, inhibition of this enzyme by pharmacological agents (DEAB) or molecular targeting (siRNA) has been shown to induce stem cell expansion and engraftment in experimental models. 44 Functional assessment of HSCs by colony forming assays Another approach to measure the functional repopulating potential of stem cell sources were initially determined by in vitro CFU cultures: CFU-granulocyte-macrophage (GM), CFU-erythroid (E) or CFU-granulocyte-erythrocyte-macrophage-megakaryocyte (GEMM). These tests are standardized and quantitative, but relatively cumbersome and time consuming. Using CFU cellculture techniques, subpopulations of stem cells within a graft were defined on the basis of their short term repopulating characteristics (STRCs) or long term repopulating characteristics. With the advent of MoAb use, additional immunophenotypically separable sub-types of human STRC were defined. As also seen in Table 3 , CD34 þ CD38 þ co-expression correlates exclusively with myeloid progeny developing rapidly post transplant, lasting 3 --5 weeks (myeloid-restricted STRC). CD34 þ CD38 --produced large numbers of B lymphoid and myeloid progeny following an initial 3 --4 week delay, lasting for the first 2 --4 months post transplant. A third population was lymphoid-restricted STRC. 35 These stem cells enumerated by in vitro short-term cultures were shown to influence engraftment in the early 1990s. Later, long-term cell cultures became available and led to estimation of stem cell numbers responsible from long-term repopulation. These longterm cultures are now being widely used in experimental stem cell studies, but correlation with clinical parameters is lacking. The immunophenotypic quantification of these long term repopulating characteristics or STRCs may replace such cumbersome techniques in future.
Progenitors of hematopoiesis involved in mobilization and engraftment The adrenergic system regulates hematopoiesis through axonal control with neuronal cells shown to grow from the BM under certain in vitro conditions. 45 --47 In addition, BM-derived MSC can differentiate to all mesodermal lineages. Furthermore, BM is composed of both cellular compartments and fatty tissue, which are all potential important sources of stem cells, and are located in the proximity of bone matrix, which is postulated to be the 'niche' within which stem and progenitor cells interact with osteoblasts to influence either the self-renewal or differentiation of stem cells. 17,48 --50 Although the impact of phenotypic HSC compartments within mobilized PB on post-transplant engraftment has been analyzed considerably, there are not many data regarding the repopulating potential of these cells. However, it has been shown that BM is richer in earlier progenitors (for example, MSC) compared with PB.
Nevertheless, MSC are observed in 1 --20 Â 10 À5 of BM cells. Staining patterns using multiple Ags have revealed multiple populations some of which are summarized in Table 3 . When CD34 þ /CD90 þ , CD34 þ /AC133 þ , CD34 þ /CD38À and CD34 þ /HLA-DR --cells were analyzed, a strong correlation between the total numbers of CD34 þ 90 þ cells, and stable and efficient platelet and neutrophil engraftment was observed. CD34 þ /90 þ cells were better predictors of engraftment than the other subpopulations analyzed. 26 The number of CD34 þ / CD90 þ cells constitute approximately one-fourth of the total CD34 þ cells and are generally fewer than the CD34 þ /CD133 þ cells, but more highly represented than the CD34 þ /CD38 --cells. CD34 þ /CD90 þ cells are mobilized into blood at a maximum level a few days earlier than peak mobilization of the total CD34 þ cells. 12 Sumikuma et al. 27 have shown a stronger impact of CD34 þ CD90 þ linÀ cells than total CD34 þ cells in predicting stable long-term platelet engraftment; 80 Â 10 4 cells/kg was the minimal number required to achieve this goal. Three of five subsequent studies analyzing the threshold value for CD34 þ CD90 þ linÀ cells shared these results. 22, 26 However, as seen in Table 2 neither the threshold nor the phenotype of cells to predict platelet engraftment was found to be consistent among these trials. Of note, this population must not be confused with MSCs, which are CD34ÀCD90 þ LinÀ.
The incidence of GVHD is observed less frequently when donor cells are obtained from BM instead of PB. Although the infusion of lymphocytes following BMT has been postulated to be responsible for this effect, the role of functionally active marrow-resident MSC may also contribute to this observation. Increased clinical experience with in vitro-generated MSC use may provide evidence for their efficacious use in the treatment of extensive GVHD. 51 MSC also may contribute to engraftment when co-transplanted with CB. Moreover, there is growing evidence on a wider differentiation potential of BM over PB. The surface markers expressed on MSCs are not specific and can be shared by progenitors of other lineages, such as endothelial progenitors. The International Society for Cellular Therapy has defined the criteria for the definition of MSCs. These include the expression of CD73, CD90, CD105 but lacking CD45, CD34, CD11b, CD14, CD49a, CD79, CD19 and HLA-DR. 52 Another source of stem cells for both in vitro and in vivo studies is CB. The CD34 þ and MSC content of CB has been extensively investigated. 36, 44, 54 Recently, an updated guideline on the minimum number of CD34 þ cells within CB units acceptable for transplantation was established as 1.5 Â 10 5 CD34 þ per kg. 54 As increasing numbers of CB transplants are being utilized for elderly patients, such a guideline was highly desirable. On the basis of the 20 years of clinical experience in this field for CB transplantation, one log fewer CD34 þ cells/kg than utilized from the BM was found to be adequate. However, as previously indicated, CD34 enumeration does not measure the functional and proliferative capacity of stem and progenitor cells within CB. Attempts to quantify earlier progenitors that possess high proliferative and functional capacity have led to the application of ALDH quantification in CB transplantation. Christ et al. 35 have demonstrated subpopulations of CD34, CD133 and ALDH expressing stem cells in human CB. HSC and most myeloid-restricted STRC as well as myeloid and lymphoid-restricted STRC are also ALDH þ , suggesting that selection of ALDH þ cells for clinical transplants will not necessarily have an adverse effect on myeloid recovery with ALDH activity serving as the best predictor for longterm engraftment. One-fourth of CD34 þ cells and two-thirds of CD133 þ cells were also ALDH þ . In this study, CD133 was not expressed on most of the STRCs and did not posses a potential for either defining STRCs or predicting engraftment. Finally, these investigators suggest ALDH þ human CB cells to be responsible for long term and ALDH --cells for short-term repopulation in this experimental model. These data favor the use of ALDH-activity measurement as a valuable tool for quantification of CB stem cells.
Phenotypic similarities between the stem cells of cancer, embryogenesis and hematopoiesis The phenotypic markers of normal and cancer stem cells share many common features. The developing molecular technologies carry the potential to capture such cells before they are differentiated or lost under unnatural in vitro conditions. ALDH is among those properties shared by both early progenitors and cancer cells. Higher activity of ALDH is correlated with increased tumorigenicity, resistance, metastasis potential and reduced survival. 17, 44 Likewise, embryonic stem cells express markers that are shared by differentiated cells. In contrast, these very immature cells possess transcription factors (OCT 4, SOX2 and NANOG) that have been identified to be specific for embryonic stem cells. These molecular markers can be measured by quantitative PCR enabling quantification of embryonic stem cells too. In addition, simultaneous immunophenotyping with a surface embryonic stem cell marker (SSEA-1) increases the specificity and sensitivity of these methods. Recently, it has been demonstrated in a murine model that a surface T-cell Ig mucin (TIM3) was present on human Lin --CD34 þ CD38ÀCD90À leukemia stem cells, but not on the normal Lin --CD34 þ CD38ÀCD90 þ HSCs. 55 This finding is notable as it offers the possibility of mapping the variety of pre-leukemic molecular mutations leading to leukemia, as well as the capacity to prospectively isolate normal SC from these patients for autotransplantation. All these complex relationships are most intriguing, but outside the scope of this review.
Future considerations These recent developments in flow cytometry and molecular methods will hopefully bring further depth and greater understanding into clinical practice. On the basis of current data, the authors recommend initiation of prospective trials analyzing the composition of harvested grafts, in addition to the traditional precryopreservation HSC counts, post-thaw stem cell counts and viability assessments. Further inroads into ex vivo graft engineering based on specific patient needs such as tumor cell purging for autologous or T cell removal for allogeneic transplants should improve clinical outcomes. Such ex vivo manipulations might also serve well to boost patient resistance to selected infectious agents. In addition to increasingly sensitive and precise cytometric methods emerging to detect minimal residual hematopoietic diseases ultimately treated by BMT, new techniques are being developed to quantify stem cells based on their mRNA expression and proteomic properties. 56, 57 Such efforts as these should bring improved clarity to the pathogenesis of delayed or impaired engraftment kinetics. The consequences of delay or incomplete reconstitution include use of costly blood products and/or antimicrobials, leading to increased morbidity and mortality. Earlier recognition of insufficient graft composition and/or prediction of implant failure should certainly improve transplant success and the well-being of the patient.
CONCLUSIONS
Despite more than 60 years of experience in hematopoietic cell transplantation, our current clinical nomenclature is essentially still not particularly accurate with respect to the definition of what we refer to as 'stem cell' transplantations. The actual CD34 þ inoculum consists of heterogeneous populations of progenitor and less differentiated cell populations. Ex vivo expansion of CB cells and introduction of MSC to clinical practice are attempts towards this goal, which at the present time have not found utility as routine treatments. However, our knowledge of hematopoiesis and tools to define stem cell subsets both phenotypically and functionally are ready to be implemented to clinical practice; it is a propitious time to introduce additional characterization with MoAbs to CD90, CD133 and possibly CD105 into our current panel of HSC quantification. With antibodies against ALDH, functional HSC quantification is gaining importance. The viability of thawed cells should be uniformly measured by flow cytometry as this measure is capable of influencing the engraftment fate. The authors, based on current evidence recommend enumeration of viable and functional stem cell subsets before the administration of these cells in the clinic. Thus, with the greater collaborative effort between cytometrists and transplant physicians we hope to be able to unveil problems related to engraftment kinetics and improve success rates.
